• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    High Drug Loading Amorphous Solid Dispersions

    Parenteral Drug Delivery Trends

    Selecting the Right Outsourcing Model for Emerging Biotech

    Inhaled Drug Delivery Technology

    The Future of Biologics: Accelerating Production, Reducing Costs
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    High Purity New England Bolsters Biopharma Solutions Services

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    Covectra Introduces Next-Gen Serialization Solution
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    C2 Pharma Completes Multiple Regulatory Filings

    Bormioli Opens New Glass Research Center

    Why Increasing Solubility May Not Improve Bioavailability - In Vitro Predictions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Covectra Introduces Next-Gen Serialization Solution

    Bormioli Opens New Glass Research Center

    Centrient Pharmaceuticals to Acquire Astral SteriTech

    Seasonal Vaccine Manufacturing

    PwC Joins Medicines Manufacturing Innovation Centre
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply

    CatSci Opens New Site in UK

    Pfizer Partners with Medicines Manufacturing Innovation Center

    CrownBio & JSR Life Sciences Partner with Cambridge Quantum Computing

    Stevanato Group Launches AI Platform
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    Almac Group

    Syngene

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Almac Group

    Baxter BioPharma Solutions

    Alcami

    PCI Pharma Services

    Adare Pharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Almost Like the Olympics:

    “Smaller, Faster, Smarter”

    Almost Like the Olympics:
    Emil W. Ciurczak, DoraMaxx Consulting05.05.20
    I recently saw a documentary about computers. A few years ago, the most powerful computer was a Cray. It was about the size of a Mini Cooper (on end): 77 in. x 263 x 104 in. and weighed 5.5 tons and cost $7.9 million (1977). With 8.4 Mbytes memory and 303 Mbytes memory, running at 80 MHz, it was the “screamer” of the time. Each couple of years, computer advances made these specs better and better. However, an Apple Watch (series 4) has a dual-core 64-bit chip, 16-GByte storage, and Wi-Fi connectivity—for several hundred dollars.

    What, might you say, has this anything to do with producing a premier pharmaceutical product? Well, unless you have been training for the first Mars expedition, you know I am a very strong proponent of PAT (Process Analytical Technologies) and QbD (Quality by Design) and, in logical progression, to CM (Continuous Manufacturing). To-date, there have been a number of reasons why both large and small Pharma companies and, by extension, their contracted partners (CMOs and CROs) have remained firmly in the 1960-70 paradigm of manufacturing their products. Why is that so?
    1. There is a lack of experience. To be fair, the universities are just catching up with the changes in manufacturing methodology, thus, a shortage of skilled, much less experienced, pharmacists, pharmaceutical process engineers, and process instrument gurus.
    2. (A supposed) Lack of liquid assets. One example of a PAT tool was the first NIR chemical imaging device. While incredibly versatile, allowing a 3-D map (X-Y picture based on >80,000 pixels, with each PIXEL containing a full NIR spectrum) to be drawn, showing a wealth of information. Sadly, the final cost just before it ceased to be sold was North of $500,000. All the larger Pharma companies had ONE, while few, if any, smaller companies could afford one.
    3. Lack of incentive (Governmental). Under the “batch mode” form of manufacture, there are, in reality, few to no controls (assays/monitors) before the batch is finished and final tests performed. If there is a chance that the batch contains outliers, it is not in the best interests of the company to analyze more than the minimum 20 units from a batch that could be as large as 5 million tablets or capsules! The PAT and following FDA and ICH Guidances were distinctly labeled “voluntary,” allowing the companies to ignore them and shout, “Damn the torpedoes. Full speed ahead!”
    4. Lack of monetary pressure. This is because the industry lobbyists have successfully prevented any price controls or the ability of Medicare to negotiate prices, country-wide. So, even if (when) a number of batches fail or need to be recalled, the financial loss can be covered by raising the price of other lots, therefore, making change(s) in testing/control methodology uneconomical. Why change your way of producing product when nothing seems to diminish profits?
    However, to quote the Nobel Laureate Robert Zimmerman (Bob Dylan, to you), “The times, they are a changing.’” Numerous countries have made moves to lower the cost of medicines to their “National Health Services.” Germany, for example, has a law that mandates a new drug for a particular illness (e.g., cancer) cannot cost more than existing drugs unless a demonstrable improvement or advantage exists. Numerous states in the U.S. have rules that allow a pharmacist to substitute a generic product for a name brand. In some states, this is mandatory, unless the physician specifically states the name brand be used.

    If Congress finally allows Medicare to negotiate drug prices, the pressure on price levels and profits will increase. There is some room for lowering prices, but, at some point, major companies will have to cede all sales of name products to generics. The answer, of course, is improve the way that the products are manufactured. Let me see, is there a way to speed production, lower costs, AND improve quality? Yes! With PAT, QbD, and, eventually, CM. But it costs money and time to convert. However, there are a number of lights at the end of the tunnel.

    Starting a few years ago, smaller instruments began to appear at trade shows. When the telecom industry imploded in the late 1990s, the technologies used to sense and re-transmit multiple voice and data streams turned out to be exactly what was needed for rapid and sensitive spectroscopic instruments:
    1. Sensitive detectors. The most popular (both with spectroscopists and telecom technicians) material for low noise and high precision when impinged with a multi-frequency mix was indium gallium arsenide (InGaAs). However, the high demand caused the price to be very high. I asked the president of a NIR company how much a diode-array of InGaAs would cost. He said $10,000. When I asked about buying in bulk, he said $10,000 apiece. This at a time when a typical high end NIR spectrometer could be purchased for ~$45,000. When you figure you need to sell an item between 2.5 to 4 X the cost of manufacture, adding one of these superior detectors could have added $25-40,000 more to the price. Assuming you could actually find InGaAs, since the telecom companies were hoarding it. When the telecom bubble burst, there were warehouses of InGaAs available, so the cost of a detector dropped to the $100 range.
    2. Novel wavelength selectors. In order to accurately resend undersea signals after detecting them, telecom used various MEMS (micro-electro-mechanical systems) to differentiate between numerous phone calls and data streams. These are also excellent for dividing a spectrum into individual wavelengths, so, when the manufacturers of these units had a choice of closing or changing direction from telecom to analytical monitoring, the choice was clear.
    3. Faster/smaller computers. Already mentioned above, the cost per gigabyte of storage and speed of calculation has dropped so greatly that placing monitors in a process stream is almost trivial. In addition, almost all new equipment/monitors are equipped with Wi-Fi, allowing networking between various monitors, allowing immediate feed-back/feed-forward control of the process.
    More new “toys” are also available for immediate injection into the process stream, every month. When we had a number of patients die from adulterated heparin from China, the FDA and USP did intensive work and concluded that 2-D NMR was the best way to ID and quantify heparin. The biggest set-back to smaller companies and contract manufacturers was the cost of purchase and operation of the unit used for the research. The unit could be more than $500,000 and the liquid helium needed to maintain the magnet and the liquid nitrogen used to slow the evaporation of the helium can cost up to $10,000 per day.

    There are now at least two models on the market that have some very attractive parameters: 1) low price (under $70,000) and 2) the ability to work at room temperature. With this tool, alone, smaller companies are able to compete for the heparin market. It is also good to know that these are quite good for any company that synthesizes APIs (small molecule actives) or purifies biomolecules, allowing them to do internal testing and not depend on expensive third-party analyses.

    Low cost mass spectrometers (MS) are also available and are readily available for freeze-drying and headspace analysis of bioreactions. The purpose of following a lyophilization (freeze-drying) process is to assure that the off-gassing is primarily the solvent(s) (water and or organic solvents). In addition, the MS follows any nitrogen peak; the presence of nitrogen indicates a potential leak in the gaskets, preventing a good vacuum from being achieved. The headspace analysis of a fermentation or other bioreaction is a good indicator of the bioreaction’s progress. Formerly, expensive and large MS instrumentation precluded ease of use in a process stream. Small, more mobile units are both less expensive and process hardened.

    Ion Mobility “Spectroscopy” is another tool for fast analysis. Previously used for residues (cleaning validation, surfaces at airports), there have been many papers published where it has been used as a replacement for either gas or liquid chromatography, generating “chromatograms” in roughly 20 milliseconds. This allows it to be used as a process tool for liquid reactions (bio-fermentations, API synthesis) in nearly real-time.

    As spectrometers (NIRS, Raman, TeraHertz) become faster, smaller, and less expensive, they can be used for real-time analysis of dosage forms or following the coating process. NIR-based units are already available and being used that are capable of measuring tablets for content uniformity and predicting dissolution profiles for 100,000 tablets per hour per line—multiple lines may be run, using fiber optic probes. One unit also uses a directed air, or nitrogen, jet to reject any tablet/capsule immediately after it being analyzed as “failing” either assay or dissolution prediction. This means that every dosage form arriving at the packaging line has been examined, eliminating rejected batches and recalled lots. The unit price is in the $100,000 range; far less than the cost of a recalled batch.

    The bottom line to all these advances is that they have levelled the playing field—PAT monitoring and control and QbD for the flexibility of modifying process parameters, on the fly (based on data from monitors). These technologies are well within the budgets of smaller generics or contract manufacturers, allowing them to continue to lower prices while simultaneously improving the quality of the products.

    As usual, I will point out a financial benefit of these units’ application: since each step has a potential to destroy the product quality, assuring each step and preventing even one lot would immediately present the company with a ROI, higher than the investment. All we need is the will to use these new mini-wonders of technology.


    Emil W. Ciurczak
    DoraMaxx Consulting

    Emil W. Ciurczak has worked in the pharmaceutical industry since 1970 for companies that include Ciba-Geigy, Sandoz, Berlex, Merck, and Purdue Pharma, where he specialized in performing method development on most types of analytical equipment. In 1983, he introduced NIR spectroscopy to pharmaceutical applications, and is generally credited as one of the first to use process analytical technologies (PAT) in drug manufacturing and development.

    Related Columns

    • Biologics, Proteins, Vaccines
      Vaccines 2021

      Vaccines 2021

      Looking at the behavioral economics of vaccinations.
      Ben Locwin, Contributing Editor 01.27.21

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20


    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20

    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20


    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20

    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20

    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20


    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20

    • Supply Chain
      What We Have is Failure to Communicate

      What We Have is Failure to Communicate

      When it comes to implementing track and trace technology, why is Pharma dragging its feet?
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.20


    • Vision: 2020

      Vision: 2020

      You have exactly 366 days in 2020 to bring your clarity of vision to reality.
      Ben Locwin 01.28.20

    • Solid Dosage/Creams/Ointments
      The “Greening” of Solid Dosage Form Manufacturing

      The “Greening” of Solid Dosage Form Manufacturing

      Going “green” can mean saving big bucks for pharma manufacturers.
      Emil W. Ciurczak, DoraMaxx Consulting 11.20.19

    • When Life Gives You Lemons…Raise Your Drug Prices

      When Life Gives You Lemons…Raise Your Drug Prices

      The hidden effect of economic models on global drug supply and shortages.
      Ben Locwin 11.20.19

    Trending
    • Catalent Acquires Delphi Genetics
    • Inside A Vaccine Trial
    • Wavelength Pharmaceuticals Acquires Majority Stake In Vanamali Organics
    • Century Therapeutics Significantly Expands Capabilities
    • Pfizer Selects Seven Bridges To Support RNA Sequencing Data
    Breaking News
    • High Purity New England Bolsters Biopharma Solutions Services
    • AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    • CatSci Opens New Site in UK
    • Pfizer Partners with Medicines Manufacturing Innovation Center
    • Covectra Introduces Next-Gen Serialization Solution
    View Breaking News >
    CURRENT ISSUE

    January/February 2021

    • High Drug Loading Amorphous Solid Dispersions
    • Parenteral Drug Delivery Trends
    • Selecting the Right Outsourcing Model for Emerging Biotech
    • Inhaled Drug Delivery Technology
    • The Future of Biologics: Accelerating Production, Reducing Costs
    • Business Intelligence For (and From) the Lab
    • Communicating Your Contracting Priorities to Your Drug Company Customers
    • COVID-19 Impact Report
    • The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    New FDA Traceability Rule Appears to Omit Dietary Supplement Manufacturers
    Clinical Trial Finds Metabolic Benefits for Polyphenols Formula
    JRF Technology Debuts Elderberry Oral Film Strip
    Coatings World

    Latest Breaking News From Coatings World

    OQ Chemicals Increases Carboxylic Acids, Esters Prices
    Sensory Analytics Announces Issuance of Broad New Patent Covering Coating Thickness Measurement
    Arkema Reports Full-year 2020 Results
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Japan to Lead APAC Assisted Reproductive Technology Devices Market
    Portescap Slotless Brushless DC Motors Receive ISO 13485 Certification
    FDA Breakthrough Device Designation Given to MI Transcatheter Heart Pump
    Contract Pharma

    Latest Breaking News From Contract Pharma

    High Purity New England Bolsters Biopharma Solutions Services
    AMRI Contributes to Efforts to Increase COVID-19 Vax Supply
    CatSci Opens New Site in UK
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Inahsi Naturals Achieves EU Compliance
    Biden Prioritizes PPP Relief for the Beauty Industry
    Christie Brinkley Joins SBLA Beauty
    Happi

    Latest Breaking News From Happi

    Clean Beauty Collective Supports EarthDay.org
    Freckle Pens Are Spot On!
    The Detox Market Partners with Good Face Project
    Ink World

    Latest Breaking News From Ink World

    Etiflex Enters New Markets with Nilpeter FA-22 Installation
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Lowe-Martin Adds 2 KODAK NEXFINITY Digital Presses
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    UFlex adds capacity in packaging films
    CEC expands into labels and packaging with Heidelberg
    ABG delivers Digicon Series 3 to UK printer
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Mexico City Single-Use Plastics Ban Leads to Tampon Shortage
    Believe Diapers Launch in U.S.
    Forbes Ranks Rockline Among Best U.S. Employers
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Kaia Health Unveils Next-Gen Complete MSK Care Solutions
    First Implantation of CTL Amedica's Minimally Invasive Flex Tower
    NuVasive Nabs Simplify Medical for $150M
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    RFID Locks Market to Reach $9.93 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login